SCHEMBL319454

SCHEMBL319454

COc1ccc(CNc2ncns2)c(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.55
CYP1A2 P05177 14/20 0.51
CYP3A4 P08684 14/20 0.51
CYP2D6 P10635 14/20 0.51
TSHR P16473 13/20 0.51
CYP2C19 P33261 13/20 0.51
CLK4 Q9HAZ1 9/20 0.51
ALDH1A1 P00352 6/20 0.51
LMNA P02545 5/20 0.51
HSD17B10 Q99714 5/20 0.51
MAPK1 P28482 4/20 0.51
USP2 O75604 3/20 0.51
ALOX15 P16050 2/20 0.51
CYP2C9 P11712 5/20 0.50
HIF1A Q16665 2/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 1/20 0.49
ERBB2 P04626 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29736330 1.00 APLNR (0.55) APLNRCYP1A2CYP3A4CYP2D6TSHR
SCHEMBL15031507 0.86 TSHR (0.45) APLNRCYP1A2CYP3A4CYP2D6TSHR
SCHEMBL15031637 0.86 TSHR (0.41) APLNRCYP1A2CYP3A4CYP2D6TSHR
SCHEMBL16020168 0.84 L3MBTL1 (0.41) APLNRCYP1A2CYP3A4CYP2D6TSHR
SCHEMBL15012022 0.79 NPC1 (0.48) CLK4LMNAHTTMAPTMEN1
SCHEMBL322837 0.78 GAA (0.60) APLNRCYP1A2CYP3A4CYP2D6TSHR
SCHEMBL14921907 0.77 APLNR (0.54) APLNRCYP1A2CYP3A4CYP2D6TSHR
SCHEMBL1094314 0.77 APLNR (0.54) APLNRCYP1A2CYP3A4CYP2D6TSHR
SCHEMBL16108929 0.77 APLNR (0.54) APLNRCYP1A2CYP3A4CYP2D6TSHR
SCHEMBL320227 0.77 APLNR (0.56) APLNRCYP1A2CYP3A4CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655291-A2 N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS BACKGROUND Merck Sharp & Dohme LLC (US) 2025-12-03 EP disclosed
US-12246008-B2 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels MERCK SHARP & DOHME LLC (US) 2025-03-11 US disclosed
WO-2024158653-A2 N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS BACKGROUND MERCK SHARP & DOHME LLC (US) 2024-08-02 WO disclosed
EP-3541373-B1 DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME LLC (US) 2023-11-01 EP disclosed
EP-3541373-B1 DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME LLC (US) 2023-11-01 EP disclosed
EP-3389654-B1 DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME LLC (US) 2023-08-16 EP disclosed
EP-3389654-B1 DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME LLC (US) 2023-08-16 EP disclosed
CN-110885319-B Sulfonamide compounds as sodium channel blockers and uses thereof 成都康弘药业集团股份有限公司 2022-08-12 CN disclosed
CN-110885328-B Sulfonamide compounds as sodium channel blockers and uses thereof 成都康弘药业集团股份有限公司 2022-08-12 CN disclosed
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2022-04-12 US disclosed
WO-2010079443-A1 SULFONAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-07-15 WO disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed
WO-2008118758-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (GB) 2008-10-02 WO disclosed
WO-2008118758-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12246008-B2 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels TRPV1, SCN7A, SCN1A APLNR 728/4885CYP1A2 2897/4885CYP3A4 1940/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 APLNR 1334/4885CYP1A2 2489/4885CYP3A4 2927/4885
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B APLNR 3569/4885CYP1A2 1091/4885CYP3A4 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.